Traditional Chinese Medicine Augmentation Therapy for Obsessive-Compulsive Disorder (TCMA-OCD)
Study of Traditional Chinese Medicine Augmentation Therapy for Obsessive-Compulsive Disorder With Nonresponse to Initial Treatment
Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent intrusive obsessive thoughts, urges, and ritualized compulsive behaviors. OCD often follows a chronic and protracted course with a high risk of relapse and is frequently accompanied by comorbid anxiety, depression, and other negative emotional symptoms, resulting in substantial impairment in occupational functioning, interpersonal relationships, and family and social functioning.Integrative treatment combining traditional Chinese medicine (TCM) and Western medicine may help address several limitations of conventional monotherapy, including suboptimal treatment response rates, medication-related adverse effects, the limited diversity of available therapeutic approaches, and insufficiently individualized treatment strategies, thereby offering potential clinical benefits.Chaixia Dingzhi Powder, the investigational Chinese herbal formula used in this study, was developed based on the formulation principles of two classical TCM prescriptions, Xiaoyao San (Free and Easy Wanderer Powder), documented in the Taiping Huimin Heji Jufang (Formulary of the Pharmacy Service for Benefiting the People in the Taiping Era), and Banxia Houpo Tang (Pinellia and Magnolia Bark Decoction), recorded in the Jingui Yaolue (Essentials from the Golden Cabinet). The formula was further modified according to the TCM pathophysiological characteristics of the target population, particularly liver qi stagnation with spleen deficiency, impaired qi movement, and the interaction of phlegm and qi stagnation.Therefore, this study aims to further investigate the efficacy and safety of Chaixia Dingzhi Powder as an adjunctive traditional Chinese medicine (TCM) treatment in patients with obsessive-compulsive disorder (OCD) who have demonstrated nonresponse to initial SSRI treatment, while maintaining their existing SSRI therapy at an adequate therapeutic dose or the maximum tolerated dose.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Lanying LIU
- Phone Number: 13516816012
- Email: balindaliu@126.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1)Aged 16-65 years; 2)Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3)Have received continuous SSRI monotherapy at the maximum recommended dose or maximum tolerated dose for at least 8 consecutive weeks; 4)Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score >12 or a Clinical Global Impression-Severity (CGI-S) score ≥3; 5)Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for liver qi stagnation and spleen deficiency.
Exclusion Criteria:
1)Meet the DSM-5 diagnostic criteria for any psychiatric disorder other than obsessive-compulsive disorder (OCD), with the exception of obsessive-compulsive personality disorder (OCPD); 2)Meet the criteria for treatment-resistant obsessive-compulsive disorder (TR-OCD) as defined in the Chinese Guidelines for the Prevention and Treatment of Obsessive-Compulsive Disorder; 3) Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for any syndrome other than liver qi stagnation and spleen deficiency; 4)Women who are pregnant, planning to become pregnant in the near future, or breastfeeding; 5)Have a history of substance abuse within the past 12 months; 6) Have a history of severe drug allergies; 7)Have any other condition that, in the investigator's judgment, makes them unsuitable for participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Control Group
Placebo Group |
Participants will receive Chai-Xia Ding-Zhi Powder placebo as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage. |
|
Experimental: Intervention Group
Chai-Xia Ding-Zhi Powder Group |
Participants will receive Chai-Xia Ding-Zhi Powder as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Y-BOCS Score
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-92
- ZDYN-2024-A-013 (Other Grant/Funding Number: National Administration of Traditional Chinese Medicine (NATCM))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.